TickerFacts.

Actinium Pharmaceuticals, Inc. (ATNM): Revenue

Annual figures by period end, from SEC filings.

$90.0K
Year ended 2025-12-31
-55.6%
3-year compound annual growth
$1.14M2021-12-31: $1.14M2022-12-31: $1.03M2023-12-31: $81.0K2025-12-31: $90.0K$90.0K
2021-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$90.0Kn/a2026-03-30, From 2025-01-01
No annual figure between 2023-12-31 and 2025-12-31.
2023-12-31$81.0K-92.1%2025-03-31, From 2023-01-01
2022-12-31$1.03M-10.0%2024-03-29, From 2022-01-01
2021-12-31$1.14Mn/a2023-03-31, From 2021-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Actinium Pharmaceuticals, Inc. (ATNM)2025-12-31$90.0Kn/a
Incannex Healthcare Inc. (IXHL)2025-06-30$86.0K+616.7%
iBio, Inc. (IBIO)2026-06-30$100.0K-75.0%
Silo Pharma, Inc. (SILO)2025-12-31$72.1K0.0%
BullFrog AI Holdings, Inc. (BFRG)2025-12-31$116.7Kn/a
Inovio Pharmaceuticals, Inc. (INO)2025-12-31$65.3K-70.0%
Connect Biopharma Holdings Ltd (CNTB)2025-12-31$64.0K-99.8%
Serina Therapeutics, Inc. (SER)2025-12-31$130.0K+132.1%
Avalo Therapeutics, Inc. (AVTX)2025-12-31$59.0K-86.6%

Compare ATNM, IXHL, IBIO, SILO side by side · Screen every company in Pharmaceutical Preparations ↗